Rare Disease Day With Thomas Abrams, MD; Maria Badillo, MSN, RN, OCN®, CCRP; and Ulka Vaishampayan, MD
Keira Smith
Expert Analysis
Oncology Data Advisor™ · Rare Disease Day With Thomas Abrams, MD; Maria Badillo, RN, OCN®, CCRP; and Ulka Vaishampayan, MD In honor of Rare Disease Day on February 28, the Oncology Data Advisor Editorial Board held a live panel discussion that featured updates on rare gastrointestinal cancers from Dr. Thomas Abrams, Assistant Professor of Medicine at Harvard Medical School; perspectives on nursing management of mantle cell lymphoma from Maria Badillo, Research Nurse Manager at MD Anderson Cancer Center; and updates on rare genitourinary cancers from Dr. Ulka Vaishampayan, Professor of Internal Medicine at the University of Michigan Rogel Cancer Center.  
Investigating Brentuximab Vedotin for Advanced-Stage Hodgkin Lymphoma With Habte Yimer, MD
Keira Smith
Expert Analysis
Oncology Data Advisor™ · Investigating Brentuximab Vedotin for Advanced-Stage Hodgkin Lymphoma With Habte Yimer, MD At the recent American Society of Hematology (ASH) Annual Meeting, Dr. Habte Yimer of Texas Oncology sat down with Oncology Data Advisor to elaborate on the promising results of brentuximab vedotin for patients with advanced-stage classical Hodgkin lymphoma, including the most recent data and future directions for the trial.  
Investigating Momelotinib for Treatment of Myelofibrosis With Srdan Verstovsek, MD, PhD
Lyn Brook
Expert Analysis
Oncology Data Advisor™ · Investigating Momelotinib for Treatment of Myelofibrosis With Srdan Verstovsek, MD, PhD At the recent American Society of Hematology (ASH) Annual Meeting, Dr. Srdan Verstovsek, Chief of the Section for Myeloproliferative Neoplasms in the Department of Leukemia at MD Anderson Cancer Center, sat down to discuss h...
Describing Real-World Treatment Patterns for Myelodysplastic Syndromes With Ira Zackon, MD
Keira Smith
Expert Analysis
Oncology Data Advisor™ · Describing Real-World Treatment Patterns for Myelodysplastic Syndromes With Ira Zackon, MD At the recent American Society of Hematology (ASH) Annual Meeting, Dr. Ira Zackon sat down with Oncology Data Advisor to discuss his abstract regarding real-world treatment patterns and survival outcomes among patients with myelodysplastic syndromes (MDS), including ways for making clinical trial data applicable for patients treated in the community oncology setting.  
Studying Olutasidenib in Relapsed/Refractory Acute Myeloid Leukemia With Jorge Cortes, MD
Lyn Brook
Expert Analysis
Oncology Data Advisor™ · Studying Olutasidenib in Relapsed/Refractory Acute Myeloid Leukemia With Jorge Cortes, MD At the recent American Society of Hematology (ASH) Annual Meeting in New Orleans, Jorge Cortes, Director of the Georgia Cancer Center in Augusta, Georgia, sat down with Oncology Data Advisor to discuss his presentation reg...
Additional Advances in Graft-Versus-Host Disease Research and Clinical Trials With Shernan Holtan, MD
Keira Smith
Expert Analysis
Oncology Data Advisor™ · Additional Advances in Graft-Versus-Host Disease Research and Clinical Trials: Shernan Holtan, MD At the 2022 American Society of Hematology (ASH) Annual Meeting, Dr. Shernan Holtan, Associate Professor at the University of Minnesota Medical School, presented a late-breaking abstract on the BMT CTN 1703 trial of post-transplant cyclophosphamide, tacrolimus, and mycophenolate mofetil as graft-versus-host disease (GVHD) prophylaxis after allogenic hematopoietic cell transplantation. Prior to the presentation, she sat down with Oncology Data Advisor to preview the trial's promising results and its potential to transform practice for GVHD.  
Aligning Treatment Goals and Value-Based Care in Newly Diagnosed Multiple Myeloma With Joseph Kalis, PharmD, BCOP, and Eric Cannon, PharmD, FAMCP
Keira Smith
Expert Analysis
Oncology Data Advisor™ · Aligning Treatment Goals and Value-Based Care in Newly Diagnosed Multiple Myeloma Multiple myeloma is a clonal plasma cell malignancy characterized by several cytogenetic alterations. Treatment planning for individual patients is complicated by factors such as age, frailty, comorbidities, eligibility for autolo...
Optimizing Patient Outcomes With CAR T-Cell Therapy With Ola Oluwole, MD
Keira Smith
Expert Analysis
Oncology Data Advisor™ · Optimizing Patient Outcomes With CAR T-Cell Therapy With Ola Oluwole, MD At the recent American Society of Hematology (ASH) Annual Meeting, Dr. Ola Oluwole of Vanderbilt University Medical Center, sat down with Oncology Data Advisor to discuss two of his abstracts on prophylactic corticosteroid use for patients receiving axicabtagene ciloleucel and the role of cytokine release syndrome in the efficacy of chimeric antigen receptor (CAR) T-cell therapy.  
Improving the Standard of Care for Advanced Hodgkin Lymphoma With Mitul Gandhi, MD
Keira Smith
Expert Analysis
Oncology Data Advisor™ · Improving the Standard of Care for Advanced Hodgkin Lymphoma With Mitul Gandhi, MD At the recent American Society of Hematology (ASH) Annual Meeting, updated results were presented for the SGN35-027 study of brentuximab vedotin plus nivolumab and chemotherapy for advanced-stage classical Hodgkin lymphoma. One of its authors, Dr. Mitul Gandhi of Virginia Cancer Specialists, sat down with Oncology Data Advisor while there to discuss the importance of the trial's results and the next steps for improving upon the standard of care for advanced Hodgkin lymphoma.  
Updates on Trials of Zilovertamab and Brentuximab Vedotin in Lymphomas With Hun Lee, MD
Keira Smith
Expert Analysis
Oncology Data Advisor™ · Updates on Trials of Zilovertamab and Brentuximab Vedotin in Lymphomas With Hun Lee, MD At the recent American Society of Hematology (ASH) Annual Meeting, Oncology Data Advisor met with Dr. Hun Lee of MD Anderson to discuss the two abstracts that he presented there. Dr. Lee provided an update on the promising data for zilovertamab plus ibrutinib for patients with mantle cell lymphoma (MCL), marginal zone lymphoma (MZL), and chronic lymphocytic leukemia (CLL), and for brentuximab vedotin plus nivolumab and chemotherapy for patients with Hodgkin lymphoma.  
Association of Socioeconomic Status With Treatment Adherence and Survival in Myeloma With Leon Bernal-Mizrachi, MD
Lyn Brook
Expert Analysis
Oncology Data Advisor™ · Association of Socioeconomic Status With Adherence and Survival in Myeloma: Leon Bernal-Mizrachi, MD At the recent American Society of Hematology (ASH) Annual Meeting in New Orleans, Leon Bernal-Mizrachi, MD, an Associate Professor of Medicine in the Department of Hematology and Oncology at the Emory University...
Advancing the Careers of Women in Hematology With Ariela Marshall, MD
Keira Smith
Expert Analysis
Oncology Data Advisor™ · Advancing the Careers of Women in Hematology With Ariela Marshall, MD At the recent American Society of Hematology (ASH) Annual Meeting, Ariela Marshall, MD, Director of the Women's Hemostasis and Thrombosis Program and Associate Professor of Clinical Medicine at Penn Medicine, sat down with Oncology Data Advisor to talk about the ASH Women in Hematology Working Group, a group committed to career advances and leadership opportunities for women in hematology.  
Factors Leading to Black Patient Disparities in Hematology Trials With Shakira Grant, MBBS
Keira Smith
Expert Analysis
Oncology Data Advisor™ · Factors Leading to Black Patient Disparities in Hematology Trials With Shakira Grant, MBBS At the recent American Society of Hematology (ASH) Annual Meeting, Shakira J. Grant, MBBS, an Assistant Professor of Medicine at the University of North Carolina at Chapel Hill, sat down with Oncology Data Advisor to discuss her research she presented, "If You Don't Trust Your Doctor That Much…You'd Feel Less Confident Doing a Research Study": Factors Influencing Black Patient Participation in Hematology Trials.
Making Health Care Accessible for Acute Myeloid Leukemia Patients With Ian Bouligny, MD
Keira Smith
Expert Analysis
Oncology Data Advisor™ · Making Health Care Accessible for Acute Myeloid Leukemia Patients With Ian Bouligny, MD At the 2022 American Society of Hematology (ASH) Annual Meeting, Dr. Ian Bouligny, Hematology/Oncology Fellow at Virginia Commonwealth University (VCU) Massey Cancer Center, spoke with Oncology Data Advisor about his abstract regarding health care disparities faced by Black patients with acute myeloid leukemia (AML). Dr. Bouligny explains the factors that contribute to treatment disparities and shares strategies for equalizing health care accessibility on both the local and the national levels.  
Creating Valuable Education for the Hematology/Oncology Fellow With Ronak Mistry, DO, and Vivek Patel, MD
Keira Smith
Expert Analysis
Oncology Data Advisor™ · Creating Valuable Education for the Hematology/Oncology Fellow: Ronak Mistry and Vivek Patel At the 2022 American Society of Hematology (ASH) Annual Meeting, Oncology Data Advisor sat down with Dr. Ronak Mistry and Dr. Vivek Patel, Clinical Fellows in Medicine at Vanderbilt University and hosts of The Fellow on Call podcast. Dr. Mistry and Dr. Patel share their passion for creating education geared towards fellows and the valuable experience of attending ASH as a trainee.  
Dynamic Risk Classification of Patients With Smoldering Multiple Myeloma With Luis Gerardo Rodríguez-Lobato, MD, PhD
Keira Smith
Expert Analysis
Oncology Data Advisor™ · Dynamic Risk Classification of Smoldering Myeloma With Luis Gerardo Rodríguez-Lobato, MD, PhD At the recent American Society of Hematology (ASH) Annual Meeting, Luis Gerardo Rodríguez-Lobato, MD, PhD, Specialist in Hematopoietic Stem Cell Transplant and Researcher at the Hospital Clínic de Barcelona and barnaclínic+, sat down with Oncology Data Advisor to discuss his research regarding dynamic risk classification for patients with smoldering multiple myeloma and how such a strategy can help clinicians predict the course of disease.  
Understanding Multiple Myeloma Treatment Patterns and Sequencing With Robert Rifkin, MD, FACP
Keira Smith
Expert Analysis
Oncology Data Advisor™ · Understanding Multiple Myeloma Treatment Patterns and Sequencing With Robert Rifkin, MD At the recent 64th American Society of Hematology (ASH) Annual Meeting, Dr. Robert Rifkin, Medical Oncologist and Hematologist at Rocky Mountain Cancer Centers in Denver, Colorado, sat down with Oncology Data Advisor to discuss the research that he presented, titled Impact of COVID-19 on Treatment Patterns and Management of Multiple Myeloma: Insights from the Connect® MM Registry.  
Exploring the Results of Elranatamab for Relapsed/Refractory Multiple Myeloma With Noopur Raje, MD
Lyn Brook
Expert Analysis
Oncology Data Advisor™ · Exploring the Results of Elranatamab for Relapsed/Refractory Multiple Myeloma With Noopur Raje, MD Recently, Dr. Noopur Raje, Director of the Center for Multiple Myeloma at Massachusetts General Hospital, sat down with Oncology Data Advisor at the 64th American Society of Hematology (ASH) Annual Meeting to disc...
Investigating CAR T-Cell Therapy Wait Time and High-Risk Disease Definitions in Myeloma With Samer Al Hadidi, MD, MS, FACP
Keira Smith
Expert Analysis
Oncology Data Advisor™ · Investigating CAR T Wait Time and High-Risk Myeloma Definitions With Samer Al Hadidi, MD, MS, FACP At the recent 64th American Society of Hematology (ASH) Annual Meeting in New Orleans, Dr. Samer Al Hadidi, Assistant Professor at the University of Arkansas, sat down with Oncology Data Advisor to discuss the multiple myeloma research that he presented. Dr. Al Hadidi elaborates on his studies regarding the wait list for patients who are eligible to receive chimeric antigen receptor (CAR) T-cell therapy and the variability of definitions of high-risk disease in myeloma clinical trials.  
Studying the Promising Role of Bispecific Antibodies in Multiple Myeloma With Ajai Chari, MD
Keira Smith
Expert Analysis
Oncology Data Advisor™ · Studying the Promising Role of Bispecific Antibodies in Multiple Myeloma With Ajai Chari, MD At the recent American Society of Hematology (ASH) Annual Meeting, Ajai Chari, MD, the Director of Research in the Multiple Myeloma Program at the Icahn School of Medicine at Mount Sinai, New York, sat down with Oncology Data Advisor to discuss his presentation regarding the phase 1/2 results of the MonumenTAL-1 study. This study researches the possible benefit of talquetamab, a bispecific antibody, in patients with relapsed or refractory multiple myeloma.  

Copyright © Oncology Data Advisor. All rights reserved.